<< Back
Results of Two Randomized Controlled Studies on Vasomedical EECP Therapy Presented at the American College of Cardiology (ACC) 58th Annual Scientific Session
EECP therapy improves peripheral endothelial function, reduces arterial stiffness and promotes coronary collateral growth

WESTBURY, N.Y.--(BUSINESS WIRE)--Mar. 31, 2009-- Vasomedical, Inc. ("Vasomedical") (OTC: VASO.OB), a leader in the non-invasive treatment and management of cardiovascular diseases, today announced that two presentations on the beneficial effects of EECP® external counterpulsation therapy have just been presented at the 58th Annual Scientific Session of the American College of Cardiology in Orlando.

The first presentation by Dr. Randy W. Braith, Dr. Richard C. Conti and colleagues from the University of Florida in Gainesville demonstrated that EECP therapy significantly improves brachial flow-mediated dilation, reduces arterial stiffness, increases nitric oxide release, exercise duration and peak oxygen consumption while there are no significant changes in the control group with low pressure sham EECP treatment. The consistency of all parameters examined in this study involving non-invasive measurements of endothelial functions by a world-class team of scientists, researchers, and clinicians confirms that EECP therapy improves peripheral endothelial function and reduces arterial stiffness. These vascular adaptations decrease left ventricular afterload and myocardial oxygen demand, and increase anginal threshold in patients with refractory angina.

The second presentation by Dr. Steffen Gloekler and colleagues from University Hospital in Bern, Switzerland showed that EECP therapy promotes coronary collateral growth (arteriogenesis) in a single-blinded, sham-controlled study of 15 coronary artery disease (CAD) patients, treated for 30 hours at 2-hours per daily session. Nine patients received EECP treatment with 300 mmHg of cuff inflation pressure (EECP group), six with 80 mmHg inflation pressure (sham group). Invasive coronary collateral assessment was performed at baseline and after EECP therapy using the Collateral Flow Index (CFI); a ratio of mean occlusive pressure determined invasively using a pressure guidewire distal to the balloon-occluded coronary artery and the mean aortic pressure. In the EECP group, CFI changed from 0.122 ± 0.06 to 0.210 ± 0.07, p=0.0002, and in the sham group from 0.165 ± 0.08 to 0.130 ± 0.06, p=0.04. The active EECP treatment induced a difference of CFI of 0.088 ± 0.07 versus –0.044 ± 0.07 in the sham group (p=0.00005). The study concluded that the clinical benefit of EECP for CAD patients might be explained by its arteriogenetic effect due to the increased laminar shear stress at the endothelial cell layer, improving endothelial function.

"The clinical effectiveness of EECP in the treatment of ischemic heart disease has been well established, but the multiple mechanisms of action (MOA) remain to be explored. The mounting evidence that EECP increases blood flow velocity and therefore the shear stress on the endothelium leading to improvement in endothelial function can now be recognized as one of the leading MOA. The two randomized-controlled studies presented during this ACC meeting provide definitive evidence to support the hypothesis that EECP improves endothelial function and enhances arteriogenesis by promoting collateral growth," commented Dr. Richard C. Conti, University of Florida, Gainesville, FL.

"We are pleased to see these clinical data, further exploring the mechanisms of action, continue to support the improved patient outcomes which have been experienced in the U.S. and abroad, as reported in the literature since 1992." stated Dr. Jun Ma, president and CEO of Vasomedical. "It is perhaps this increased understanding of EECP therapy," Dr. Ma continued "that is contributing to the resurgence of interest in EECP therapy that we have been seeing recently."

Further information about these studies is available at the American College of Cardiology website, www.acc.org.

About Vasomedical, Inc. and EECP® Therapy

Vasomedical, Inc. develops, manufactures and markets EECP® therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP® therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve exercise performance and quality of life for thousands of people worldwide. For more information visit www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipated,” “believes,” “could,” “estimates,” “expects,” “may,” “offers,” “plans,” “potential,” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Source: Vasomedical, Inc.

Vasomedical, Inc.
Dr. Jun Ma, President & CEO
Tarachand (David) Singh, CFO
Investor Relations:
516-997-4600 ext. 790

Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\95\95266\Disclaimers.xml'.